Latest database descriptions

Primary objective: To describe in a real life setting the evolution of fatigue in patients with moderate to severe RA during the first 4 months of RoActemra® treatment, as well as to search for predictive factors of an improvement in this symptom.

Secondary objectives:
- To describe patient baseline characteristics and level of fatigue experienced at inclusion by the patient population treated with RoActemra®;
- To evaluate the correlation between the evolutions of fatigue as assessed by FACIT-Fatigue questionnaire and VAS fatigue during the first 4 months of RoActemra® treatment;
- To evaluate the time of onset of RoActemra® effect on fatigue in a real life setting;
- To assess the correlation between evolution of fatigue and disease activity during 4 months of RoActemra® treatment;
- To evaluate the PASS of the fatigue scales (FACIT-Fatigue, VAS fatigue, SF36 vitality) after 4 months of RoActemra® treatment;
- To evaluate the correlation between evolution of fatigue and other patient reported outcomes (PROs): pain, quality of sleep, disability, SF36 vitality, anxiety, depression;
- To describe the management of RA patients treated with RoActemra®;
- To describe all adverse events occurring during the study.

Primary objectives: To describe the criteria used for therapeutic decision-making for RA patients:
- clinical, biological and radiological data, impact of RA on patients’ life according to physicians;
- impact of RA on patients’ life according to patients;
- physicians’ characteristics.

Secondary objectives:
- To describe the characteristics of the included patient population depending on treatment modifications after the inclusion visit.

Primary objective: To describe the progression-free survival of a population of patients with metastatic or locally advanced NSCLC treated with Tarceva® monotherapy whose disease has not progressed for at least nine months.

Secondary objectives:
- To describe patients’ characteristics at inclusion in the study and on initiation of treatment with Tarceva® monotherapy (demographic, clinical, and biological characteristics);
- To describe the use of Tarceva®;
- To evaluate the efficacy of treatment with Tarceva®: the best response obtained (complete response, partial response, or stabilisation), overall survival, and prognostic criteria for long-term survival on Tarceva®;
- To describe the long-term safety profile of Tarceva®;
- To describe the correlations between tumour biology and response to Tarceva®;
- To describe patient adherence to Tarceva® monotherapy using the Morisky scale;
- To describe the change in quality of life for patients treated with Tarceva® monotherapy, using the FACT-L questionnaire.

Primary objective : To describe in real life the glucocorticoid-sparing effect after 12 months of treatment with RoActemra® in patients with moderate to severe RA and to determine predictive factors.

Secondary objectives:
1. to describe the characteristics of the population at baseline;
2. to evaluate efficacy of RoActemra® (EULAR response and/or glucocorticoid dosage) in real life;
3. to describe therapeutic management of RA [glucocorticoids and/or conventional Disease-Modifying Anti-Rheumatic Drug(s) (DMARDs) in combination with RoActemra®];
4. to describe change in functional capacity of patients and impact of the disease on the patient over time during follow-up (HAQ-DI and RAID self-report questionnaires);
5. to assess safety of RoActemra®.